Navigation Links
Hyaluronic Acid Dermal Filler Market Skyrockets

The US dermal filler market is expected to grow at a compound annual growth

rate of 20% from 2006-2011, according to Millennium Research Group

WALTHAM, Mass., Feb. 20 /PRNewswire/ -- According to Millennium Research Group's Global Markets for Hyaluronic Acid in Aesthetic, Orthopedic, and Emerging Applications 2008 report, the US hyaluronic acid (HA) dermal filler market will grow at a compound annual growth rate of nearly 20% from 2006 through 2011.

Growth in this market will be driven by a rising demand for dermal filler procedures, performed primarily to correct facial blemishes, and a global population increasingly interested in cosmetic enhancement. HA dermal fillers, the second-most popular facial aesthetic treatment after botulinum toxin (Botox) injections in 2006, will experience very strong growth over the next five years because cosmetic HA injections are quick, safe, effective, and relatively inexpensive.

"Since HA is a naturally occurring compound, many patients are comfortable receiving cosmetic treatments using this product," says Jaya Classen, Senior Analyst at Millennium Research Group. "As a result, it is expected that HA dermal fillers will further penetrate the market at the expense of competing treatments, such as collagen and particle and polymer filler injections."

The Global Markets for Hyaluronic Acid in Aesthetic, Orthopedic, and Emerging Applications 2008 report includes coverage of the HA dermal filler and viscosupplementation markets in the US, Europe (France, Germany, Italy, and the UK), and Asia Pacific (Japan, China, South Korea, and Taiwan). The report provides coverage of all key industry competitors, including Allergan, Fidia Farmaceutici, Genzyme Biosurgery, Medicis Pharmaceuticals, Seikagaku Corporation, and Q-Med.

About Hyaluronic Acid

HA is a compound that is found in human connective tissue. Its degradation in deep and superficial dermal layers has been implicated in the overt signs of aging and, as a major constituent of joint synovial fluid, has been associated with the onset of osteoarthritis. Animal- or synthetically- derived HA supplements can therefore be injected directly in skin for the treatment of wrinkles and scars or into a joint for arthritic pain relief. Furthermore, because HA is naturally found in such a wide variety of tissues, many other potential applications for the compound are emerging.

About Millennium Research Group

Millennium Research Group (, a Decision Resources, Inc. company (, is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 1st EMEA application filed for product using innovative intradermal microinjection system BD Soluvia
2. PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
3. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
4. Building an Effective Sales Force to Serve the U.S. Hospital Market
5. Greenway Medical Technologies Broadens Sales Efforts With Entrance Into Federally Qualified Health Center Marketplace
6. Spectragenics Names Rpr Marketing Communications Agency of Record
7. Northfield Automation Announces Wholly Owned Subsidiary to Diversify Into Medical Device Market
8. Nano Pet Products, LLC Named Exclusive Worldwide Licensee by Schoeller(R) Technologies AG for Pet Products to Develop the Most Technologically Advanced Pet Brands on the Market Today
9. Darwin Enters into Marketing Partnership with Agency Specialty Product Network
10. Healthy Coffee International, Inc. Establishes Healthy Coffee USA, Inc. as Its Marketing Arm
11. A Favorite in France, Elgydium(R) Toothpaste Makes Entrance Into the U.S. Market
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... automated breast density assessment and enterprise analytics solutions, here at the 101st ... (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements ...
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone will ... close friend, or animal pass away, death lives among us. It is your perspective, ... from a family of 11 children, author T Sky understands that she may see ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming Dec. 8 virtual ... Essentia Health and UCare, MissionPoint Health Partners, and Intel Corp. Leaders from ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... The successful ... emerging pharmaceutical company. Because it is so important to this key industry segment, Regis ... in your IND Filing” on December 4th at 11am EST. , Federal law does ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in the ... Matrix is a long-term resorbable surgical mesh intended to support and reinforce soft ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015 Cumberland Pharmaceuticals (CPIX), today announced that ... on December 3, 2015. TIME: 3:15p.m. ET ... ET LINK: --> DATE: ... --> --> ... are invited to ask the company questions in real-time - ...
(Date:11/30/2015)... -- Varian Medical Systems (NYSE: VAR ) has signed a ... Hospitals Group, the largest hospital chain in India ... in the country. The MoU was signed by Dr. K. ... Kakkar , Varian,s India managing director, in ... , Varian intends to deploy its Access to Care program by ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
Breaking Medicine Technology: